Skip to content

Posterior Capsule Opacification (PCO) Evaluation of the AcrySof SN60AT Lens vs. SN60WF Lens

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00762021
Enrollment
104
Registered
2008-09-30
Start date
2006-12-31
Completion date
Unknown
Last updated
2010-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract

Keywords

cataract

Brief summary

To assess posterior capsule opacification (PCO) in patients implanted with either the AcrySof SN60AT lens or the AcrySof SN60WF lens.

Interventions

DEVICESN60AT

Implantation with the AcrySof Intraocular Lens Model SN60AT following cataract removal.

DEVICESN60WF

Implantation with the AcrySof Intraocular Lens Model SN60WF following cataract removal.

Sponsors

Alcon Research
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients with bilateral senile cataracts * Age \> 50 years * Fit for hospital follow ups * Pupils dilating \> 6mm preoperatively * Eyes expected to see 6/12 or better postoperatively

Exclusion criteria

* Diabetes * On treatment for glaucoma * Other ocular pathology * Previous ocular surgery

Design outcomes

Primary

MeasureTime frameDescription
Posterior Capsule Opacification (PCO)2 years after surgeryThickening and opacification of the transparent membrane on which the intraocular lens is placed assessed by taking a digital retroillumination image of each eye with a dedicated retroillumination camera system. The photographs were analyzed with POCO software to measure the percentage area of PCO in the capsulorhexis area.
100% LogMAR Best Corrected Visual Acuity (BCVA)24 months after surgeryBest spectacle corrected vision was recorded for each eye of the patients at above follow up visits. The Visual Acuity (VA) measurement was taken under high contrast (100%), which means that there was maximum contrast between the letters on the chart and the background. VA is measured in logMAR. LogMAR is the logarithm of the minimum angle of resolution. A lower logMAR value indicates better visual acuity.
9% LogMAR Best Corrected Visual Acuity (BCVA)24 months after surgeryBest spectacle corrected vision was recorded for each eye of the patients at above follow up visits. The Visual Acuity (VA) measurement was taken under low contrast (9%), which means that there was low contrast between the letters on the chart and the background. VA is measured in logMAR. LogMAR is the logarithm of the minimum angle of resolution. A lower logMAR value indicates better visual acuity.

Countries

United States

Participant flow

Recruitment details

Uncomplicated age-related bilateral cataract with the potential to see 20/40 or better in each eye

Pre-assignment details

During the preoperative exam, subjects were examined to ensure they met the inclusion/exclusion criteria.

Participants by arm

ArmCount
SN60AT
Implantation with the AcrySof Intraocular Lens Model SN60AT
52
SN60WF
Implantation with the AcrySof Intraocular Lens Model SN60WF
52
Total104

Baseline characteristics

CharacteristicSN60ATSN60WFTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
40 Participants40 Participants80 Participants
Age, Categorical
Between 18 and 65 years
12 Participants12 Participants24 Participants
Sex: Female, Male
Female
29 Participants29 Participants58 Participants
Sex: Female, Male
Male
23 Participants23 Participants46 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 520 / 52
serious
Total, serious adverse events
0 / 520 / 52

Outcome results

Primary

100% LogMAR Best Corrected Visual Acuity (BCVA)

Best spectacle corrected vision was recorded for each eye of the patients at above follow up visits. The Visual Acuity (VA) measurement was taken under high contrast (100%), which means that there was maximum contrast between the letters on the chart and the background. VA is measured in logMAR. LogMAR is the logarithm of the minimum angle of resolution. A lower logMAR value indicates better visual acuity.

Time frame: 24 months after surgery

Population: Data for all patients completing the 24 month visit were analyzed.

ArmMeasureValue (MEAN)Dispersion
SN60AT100% LogMAR Best Corrected Visual Acuity (BCVA)0.04 LogMARStandard Deviation 0.1
SN60WF100% LogMAR Best Corrected Visual Acuity (BCVA)0.07 LogMARStandard Deviation 0.2
Primary

9% LogMAR Best Corrected Visual Acuity (BCVA)

Best spectacle corrected vision was recorded for each eye of the patients at above follow up visits. The Visual Acuity (VA) measurement was taken under low contrast (9%), which means that there was low contrast between the letters on the chart and the background. VA is measured in logMAR. LogMAR is the logarithm of the minimum angle of resolution. A lower logMAR value indicates better visual acuity.

Time frame: 24 months after surgery

Population: Data for all patients completing the 24 month visit were analyzed.

ArmMeasureValue (MEAN)Dispersion
SN60AT9% LogMAR Best Corrected Visual Acuity (BCVA)0.42 LogMARStandard Deviation 0.2
SN60WF9% LogMAR Best Corrected Visual Acuity (BCVA)0.45 LogMARStandard Deviation 0.2
Primary

Posterior Capsule Opacification (PCO)

Thickening and opacification of the transparent membrane on which the intraocular lens is placed assessed by taking a digital retroillumination image of each eye with a dedicated retroillumination camera system. The photographs were analyzed with POCO software to measure the percentage area of PCO in the capsulorhexis area.

Time frame: 2 years after surgery

Population: Data for all patients completing the 24 month visit were analyzed.

ArmMeasureValue (MEAN)Dispersion
SN60ATPosterior Capsule Opacification (PCO)11.58 Percentage of PCOStandard Deviation 20.18
SN60WFPosterior Capsule Opacification (PCO)14.04 Percentage of PCOStandard Deviation 22.15

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026